Novartis Benefits From Lack of Generic Challenge
April 24 (Bloomberg) -- Bloomberg's Jonathan Ferro reports that Novartis AG saw first-quarter profit rise 7 percent as a competitor's generic version of the company’s second-best-selling medicine failed to reach the market. He speaks on Bloomberg Television's "On The Move."
Most Recent Videos
U.S. GDP Looks for a Rebound in Expanding ISM Data
46:02 - Bloomberg's Michael McKee highlights a potential path higher for U.S. GDP as ISM manufacturing numbers climb higher into expansionary territory. He speaks on "Bloomberg Surveillance." (Source: Bloomberg)